No Data
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
Hong Kong Stock Concept Tracking | It is rumored that the World Health Organization plans to include weight loss drugs in the essential directory, accelerating the development progress of weight loss drugs (with related concept stocks).
Is this the first time weight loss drugs are included in the essential medicines list? The World Health Organization responded that the relevant plan is being formulated and is expected to be released as early as August.
Selected announcements | FIH turned a profit in the first quarter year-on-year; Swire Properties plans to spin off TCPCL beverage Business for listing in Thailand.
① FIH turned a profit in the first quarter compared to the same period last year, which businesses contributed to this improvement? ② Hiap Hoe's New energy Fund generated less electricity in the first four months year-on-year, how significant is the impact?
Ge Li Pharmaceutical (01672.HK) will announce the early research results of the obesity candidate drug ASC47.
GeLi Pharmaceutical (01672.HK) announced that it will present early research results of the obesity candidate drug ASC47, which targets fat and promotes weight loss without losing muscle, in both oral and poster formats at the 32nd European Congress on Obesity (ECO 2025) to be held in Malaga, Spain. The FDA has currently approved the new drug clinical trial application for ASC47 in combination with semaglutide for the treatment of obesity.
Express News | Eagle Pharmaceuticals: Report on the results of the ASC47 study at the Europe Obesity Conference.